Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
Duke University is a private research university in Durham, North Carolina. Home of the Blue Devils, Duke University has about 15,000 undergraduate and graduate students and a world-class faculty helping to expand the frontiers of knowledge. The university has a strong commitment to applying knowledge in service to society, both near its North Carolina campus and around the world.
The University of North Carolina at Chapel Hill, established in 1789 as the first public university in the United States, is dedicated to advancing education, research, and public service both locally and globally. It offers a diverse range of undergraduate and graduate programs across various fields, including arts, sciences, law, medicine, and nursing. The university is committed to fostering the next generation of leaders through a rigorous academic environment supported by exceptional faculty and staff. Additionally, it manages an endowment fund that finances scholarships, fellowships, research initiatives, and library resources, thereby enhancing the educational experience and promoting the success of its students. Through its outreach efforts, the university aims to improve the quality of life for citizens in North Carolina, leveraging knowledge and resources to serve the community effectively.
Plakous Therapeutics, based in Winston-Salem, North Carolina, specializes in producing restorative and regenerative healing products derived from post-delivery human placentas. Founded in 2016 by Seth Tomblyn and Scott Washburn, the company manufactures biotherapeutics, including its flagship product, Protego-PD, an orally delivered acellular therapy. Plakous Therapeutics focuses on utilizing placental cytokines and growth factors to create allografts that promote and support the body's natural healing processes. By enhancing the functionality of the amniotic membrane as a drug delivery device, the company aims to provide healthcare providers and patients with effective therapeutic options grounded in scientific research and clinical evidence.
Coprata Inc. focuses on non-invasive physiological monitoring through innovative technology that allows for discreet health tracking with minimal disruption to daily life. The company is developing a Smart Sampling Toilet, a novel wastewater technology licensed from Duke University, which was created by researchers associated with the Bill and Melinda Gates Foundation. This digital health platform aims to facilitate hands-free stool sampling and automate the monitoring of bowel movements, enabling the detection and management of both acute and chronic gastrointestinal diseases. Additionally, it provides early warnings for infectious diseases, helping individuals access tools for personalized wellness monitoring.
The Company is focused on the commercialization of its first oncology application: treatment of advanced hepatocellular carcinoma. It has completed a phase II study, which shows effectiveness as well as excellent tolerability, even in previously treated patients with severely impaired liver function. See less
Plakous Therapeutics, based in Winston-Salem, North Carolina, specializes in producing restorative and regenerative healing products derived from post-delivery human placentas. Founded in 2016 by Seth Tomblyn and Scott Washburn, the company manufactures biotherapeutics, including its flagship product, Protego-PD, an orally delivered acellular therapy. Plakous Therapeutics focuses on utilizing placental cytokines and growth factors to create allografts that promote and support the body's natural healing processes. By enhancing the functionality of the amniotic membrane as a drug delivery device, the company aims to provide healthcare providers and patients with effective therapeutic options grounded in scientific research and clinical evidence.
Developer of life science platform intended to provide accurate methods to test dangerous endotoxins. The company provides advanced healthcare innovations for the detection of blood-borne pathogens, enabling physicians to develop a rapid and sensitive diagnostic for detecting bloodstream infection.
Apie Therapeutics develop and commercialize novel Apelin Receptor biased agonist drug therapies, activating the Apelinergic System focused on the promising therapy targets of the Apelinergic System.
CasTag Biosciences specializes in cell biology and regenerative medicine, focusing on revolutionizing the speed of endogenously protein analysis. The company aims to accelerate scientific discovery by offering tools that allow scientists to study novel genes in any experimental model.
Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.
Drive Therapeutics is a biotechnology company focused on enhancing treatments for retinal diseases. The company is developing therapeutics specifically aimed at addressing wet age-related macular degeneration and diabetic retinopathy, including diabetic macular edema. Through its innovative approach, Drive Therapeutics aims to provide more effective solutions for patients suffering from these serious eye conditions.
North Carolina State University is an educational institution that offers graduate and undergraduate programs. The university offers academic qualifications in engineering, agriculture, life sciences, textiles and design, natural resources, and management through 106 bachelor’s degrees, 104 master’s degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The University of North Carolina’s 17 campuses extend from the state’s mountains to the coast. More than 220,000 students are enrolled at 16 universities and the NC School of Science and Mathematics, the country’s first public residential high school for gifted students. North Carolina State University is one of the eight universities with a presence at the North Carolina Research Campus, where it operates a research and education organization devoted to food crops. In March 2008, the university also launched the University Sustainability Office in order to address environmental concerns on campus. North Carolina State University was founded on March 7, 1987.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
Chiesi USA is a specialty pharmaceutical company based in Cary, North Carolina, dedicated to the development, acquisition, and commercialization of products aimed at addressing respiratory, inflammatory, and critical care diseases. The company focuses on discovering and advancing therapies for asthma and related conditions, leveraging its expertise to identify therapeutic niches within the specialty markets. By promoting its products to healthcare professionals through targeted sales forces, Chiesi USA aims to enhance patient outcomes while also generating revenue through the marketing of approved generic products via its subsidiary, Aristos Pharmaceuticals. The company maintains a robust pipeline of development projects, reflecting its commitment to innovation in the pharmaceutical industry.
Lindy Biosciences is a development-stage protein therapeutic formulations company. Our core technology produces spherical, dense, stable particles of a therapeutic protein. These protein particles are ideal for long-term storage, or for non-standard formulations such as suspension formulations (for high-concentration delivery of antibodies), encapsulation (for sustained/controlled release), or dry powder pulmonary delivery.
PRA International is a prominent contract research organization that offers outsourced clinical development and data solution services to the pharmaceutical and biotechnology industries worldwide. The company operates through two primary segments: Clinical Research and Data Solutions. The Clinical Research segment provides comprehensive services including clinical trial management, regulatory affairs, and therapeutic expertise, along with early development services for Phase I and IIa studies. The Data Solutions segment focuses on delivering data analytics, consulting, and technology-enabled solutions to the life sciences market. With over 10,000 employees across more than 80 countries, PRA is involved in conducting clinical trials for various therapeutic areas, including oncology and immunology. The organization plays a significant role in drug development, having contributed to the regulatory approval of numerous marketed drugs. PRA International, founded in 1976 and headquartered in Raleigh, North Carolina, is committed to excellence and innovation in its partnerships with clients.
Isolere Bio is a biotechnology company dedicated to simplifying the purification processes for biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to these critical drugs, the company is developing innovative technology that utilizes a straightforward Tangential Flow Filtration (TFF) setup. This approach is designed to facilitate a seamless transition from laboratory-scale to industrial-scale production, thereby addressing the growing demand for effective biotherapeutics in research and diagnostics. Through its focus on streamlining bioprocessing, Isolere Bio aims to contribute significantly to advancements in the biopharmaceutical industry.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Higgs Boson Health is a digital health company focused on enhancing the well-being of individuals undergoing acute interventional or surgical procedures. The company has developed a healthcare mobile application that facilitates seamless communication and engagement among patients, doctors, and hospitals. This application aims to improve patient outcomes and operational efficiencies by enabling effective management of activities related to surgeries and medical procedures. By empowering all stakeholders in the healthcare process, Higgs Boson Health strives to support healthier lives for patients during critical medical interventions.
Enzene Biosciences is a biotechnology company focused on providing affordable medicines through the development of biosimilars. The company employs advanced technologies, analytics, and a state-of-the-art manufacturing facility to enhance the efficiency of its operations. Enzene specializes in cloning, process development, and novel formulation development, which enables clients to leverage innovative solutions in commercial microbial manufacturing. By fostering strategic global alliances, Enzene aims to broaden the reach of its disruptive technologies and improve healthcare outcomes worldwide. The company is recognized for its strong workplace culture, making it an attractive employer in the biotech sector.
East Carolina University (ECU), founded in 1907 and located in Greenville, North Carolina, is a comprehensive educational institution offering a wide range of graduate, postgraduate, and doctoral programs across various disciplines, including health sciences, medicine, nursing, fine arts, communication, technology, and business. Renowned for its Brody School of Medicine, ECU ranks highly in primary care and rural medicine, emphasizing research and innovation, particularly in robotic surgery. The university is also recognized for its College of Education, whose graduates have achieved state and national accolades. In addition to traditional courses, ECU provides adult learning opportunities and distance education. Student support services encompass career counseling, health services, and study abroad programs. The ECU Foundation, established in 1963, manages an endowment fund aimed at enhancing the university's academic programs and research initiatives through private contributions. As a non-profit institution, ECU operates under the University of North Carolina system, committed to fostering educational excellence and community engagement.
BiomedInnovations is a medical device company that makes precision air and fluid flow devices, including products for lung ventilators and ex-vivo organ and tissue perfusion.
Tellus Therapeutics is a biopharmaceutical company focused on creating innovative treatments for newborns facing perinatal brain injuries. The company specializes in developing small molecules derived from human maternal breast milk, which aim to promote the regeneration of myelin-producing oligodendrocytes and mitigate white matter injury in premature infants. By addressing unmet medical needs, Tellus Therapeutics enables healthcare providers to offer effective interventions for all babies at risk of brain injury, thereby improving neurodevelopmental outcomes for these vulnerable children.
North Carolina State University is an educational institution that offers graduate and undergraduate programs. The university offers academic qualifications in engineering, agriculture, life sciences, textiles and design, natural resources, and management through 106 bachelor’s degrees, 104 master’s degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The University of North Carolina’s 17 campuses extend from the state’s mountains to the coast. More than 220,000 students are enrolled at 16 universities and the NC School of Science and Mathematics, the country’s first public residential high school for gifted students. North Carolina State University is one of the eight universities with a presence at the North Carolina Research Campus, where it operates a research and education organization devoted to food crops. In March 2008, the university also launched the University Sustainability Office in order to address environmental concerns on campus. North Carolina State University was founded on March 7, 1987.
The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.
UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.
The University of North Carolina at Chapel Hill, established in 1789 as the first public university in the United States, is dedicated to advancing education, research, and public service both locally and globally. It offers a diverse range of undergraduate and graduate programs across various fields, including arts, sciences, law, medicine, and nursing. The university is committed to fostering the next generation of leaders through a rigorous academic environment supported by exceptional faculty and staff. Additionally, it manages an endowment fund that finances scholarships, fellowships, research initiatives, and library resources, thereby enhancing the educational experience and promoting the success of its students. Through its outreach efforts, the university aims to improve the quality of life for citizens in North Carolina, leveraging knowledge and resources to serve the community effectively.
Cereius, Inc. is a privately owned, pre-clinical stage company based in Durham, North Carolina, focused on developing innovative small-molecule therapies for treating brain metastasis specifically in patients with HER2-positive breast cancer. Established in 2017, the company employs novel radiolabeling chemistries that improve the uptake and retention of radionuclides in targeted tumors while reducing uptake in normal tissues. This approach aims to significantly enhance both the therapeutic index and diagnostic contrast of targeting agents, positioning Cereius as a key player in the advancement of treatment options for solid tumor brain metastasis.
Duke BioRepository & Precision Pathology Center (BRPC), Duke’s largest human tissue biobank. BRPC stores samples from consented patients for use in research.
Operator of an agricultural biotechnology company committed to developing and producing allergen-free peanuts. The company develops its agricultural products using technology like genomics, proteomics, plant tissue culture and plant propagation, providing consumers with high-value agricultural products that enhance and save human lives.
Isolere Bio is a biotechnology company dedicated to simplifying the purification processes for biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to these critical drugs, the company is developing innovative technology that utilizes a straightforward Tangential Flow Filtration (TFF) setup. This approach is designed to facilitate a seamless transition from laboratory-scale to industrial-scale production, thereby addressing the growing demand for effective biotherapeutics in research and diagnostics. Through its focus on streamlining bioprocessing, Isolere Bio aims to contribute significantly to advancements in the biopharmaceutical industry.
IMMvention Therapeutix, Inc. is dedicated to improving the lives of patients suffering from auto-inflammatory diseases with significant unmet medical needs. The company focuses on discovering and developing novel therapies that inhibit inflammation caused by the activation of multiple inflammasomes. Unlike existing approaches that target single receptor inflammasome inhibition, IMMvention's innovative pipeline aims to address conditions where multiple inflammasomes are involved, enhancing the effectiveness of treatments for rare auto-inflammatory diseases, such as Bullous Pemphigoid. Co-founded in 2017 by leading scientists from the University of North Carolina-Chapel Hill, including Dr. Jenny Ting, the company leverages its team's expertise in immunology and innate immunity. Funding has been secured through NIH SBIR grants, North Carolina Biotechnology Center, and partnerships with pharmaceutical companies, enabling the advancement of its preclinical therapeutics pipeline aimed at transforming clinical outcomes for patients with orphan diseases.
Arrevus, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for orphan diseases. Its product pipeline includes ARV-1801, a oral dosing regimen and formulation of fusidic acid for the treatment of pulmonary exacerbations in cystic fibrosis; ARV-1907, an inhaled formulation of fusidic acid for the treatment of persistent staphylococcus aureus lung infections in cystic fibrosis patients; ARV-1502, an engineered inhibitor of bacterial DnaK for cancer treatment; and ARV-1802, a leptin receptor antagonist for cancer treatment. The company was incorporated in 2015 and is headquartered in Raleigh, North Carolina.
Aniluxx Biotechnology is a development stage biopharmaceutical company with a mission to improve companion animal health and well-being. The Company’s strategy is to translate its deep pipeline of topically formulated therapeutics, predicated on compounds that have already been identified as safe and effective in humans, into therapies for dogs, cats, and horses, that are easy to apply, virtually unnoticeable, and absent the harsh side effects of systemic medicines.
Emergo Therapeutics, Inc. is a pharmaceutical company based in Durham, North Carolina, founded in 2016. The company focuses on developing therapeutic drugs aimed at modulating inflammatory cytokines and enhancing immune system function. Its primary product in development is norketotifen, which is intended for the treatment of uncomplicated influenza and flu-like illnesses. Emergo Therapeutics seeks to reduce the production of inflammatory cytokines from mast cells, with a broader goal of addressing various infectious diseases and improving health outcomes related to inflammation.
Redbud Labs, Inc. specializes in the development and manufacturing of MEMS and microfluidics technologies tailored for the life science industry. The company produces actuated surface-attached posts films, which facilitate the manipulation of fluids, cells, and reagents at the microscale, thereby enhancing mixing efficiency and reducing assay times. Additionally, Redbud Labs is known for its innovative MXR, the first fully modular microfluidic mixer, utilized by leading biotechnology firms to enhance assay performance. The company offers cartridge-based automated sample preparation platforms, which simplify laboratory workflows while maintaining high performance. Founded in 2010 and based in Chapel Hill, North Carolina, Redbud Labs draws on advanced research from the University of North Carolina to provide solutions that address complex microfluidic challenges in research, drug discovery, and diagnostics.
TregTherapeutics is a preclinical stage company based in North Carolina, specializing in the development of innovative therapies for multiple sclerosis. The company is focused on creating a tolerogenic vaccine that leverages the regulatory functions of T-regulator cells (Tregs) to modulate the immune response. This approach aims to reverse the inflammatory attacks on the nervous system that characterize multiple sclerosis while promoting an anti-inflammatory response. TregTherapeutics has secured an exclusive license for its proprietary technology from East Carolina University, positioning it to potentially transform treatment outcomes for patients suffering from autoimmune diseases. Its commitment to advancing universal tolerance induction therapy reflects a strategic focus on addressing the underlying causes of neurodegenerative disorders.
Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
Dualogics is a biotechnology company housed at the University of North Carolina at Chapel Hill. Dualogics uses a proprietary bispecific antibody technology to create bispecific antibody products with superior properties compared to alternative methods. Our goal is to collaborate with academic and industrial partners to develop and test a suite of multifunctional therapies and reagents.
InnAVasc Medical, Inc. is a medical device company based in Durham, North Carolina, focused on developing innovative solutions for vascular access in hemodialysis. Founded by surgeons from Duke University, the company has created the Bullet Proof Vascular Access Graft, an advanced arteriovenous graft designed with two multilayer cannulation chambers. This technology features low bleed capabilities and is engineered to resist posterior and sidewall needle penetration, thereby minimizing the risk of needle cannulation injuries. By modifying existing synthetic vascular grafts, InnAVasc aims to enhance immediate hemodialysis access and improve graft access safety, ultimately reducing the likelihood of adverse events and device failures associated with repeated vascular access procedures.
Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.
Cereius, Inc. is a privately owned, pre-clinical stage company based in Durham, North Carolina, focused on developing innovative small-molecule therapies for treating brain metastasis specifically in patients with HER2-positive breast cancer. Established in 2017, the company employs novel radiolabeling chemistries that improve the uptake and retention of radionuclides in targeted tumors while reducing uptake in normal tissues. This approach aims to significantly enhance both the therapeutic index and diagnostic contrast of targeting agents, positioning Cereius as a key player in the advancement of treatment options for solid tumor brain metastasis.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Baebies, Inc. is a company that focuses on manufacturing screening and pediatric testing equipment for newborns. Established in 2014 and based in Durham, North Carolina, Baebies produces SEEKER, a laboratory solution for newborn screening that conducts multiple assays simultaneously by measuring lysosomal enzyme activity from a single dried blood spot. Additionally, the company offers FINDER, a near-patient testing device designed for pediatric applications. Baebies aims to enhance early disease detection and improve diagnostic capabilities through its innovative digital microfluidics technology, which optimizes the diagnostic yield from minimal blood samples. The company serves hospitals and public health laboratories, with a mission dedicated to saving lives and improving health outcomes for children by providing advanced testing solutions.
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Baebies, Inc. is a company that focuses on manufacturing screening and pediatric testing equipment for newborns. Established in 2014 and based in Durham, North Carolina, Baebies produces SEEKER, a laboratory solution for newborn screening that conducts multiple assays simultaneously by measuring lysosomal enzyme activity from a single dried blood spot. Additionally, the company offers FINDER, a near-patient testing device designed for pediatric applications. Baebies aims to enhance early disease detection and improve diagnostic capabilities through its innovative digital microfluidics technology, which optimizes the diagnostic yield from minimal blood samples. The company serves hospitals and public health laboratories, with a mission dedicated to saving lives and improving health outcomes for children by providing advanced testing solutions.
Baebies, Inc. is a company that focuses on manufacturing screening and pediatric testing equipment for newborns. Established in 2014 and based in Durham, North Carolina, Baebies produces SEEKER, a laboratory solution for newborn screening that conducts multiple assays simultaneously by measuring lysosomal enzyme activity from a single dried blood spot. Additionally, the company offers FINDER, a near-patient testing device designed for pediatric applications. Baebies aims to enhance early disease detection and improve diagnostic capabilities through its innovative digital microfluidics technology, which optimizes the diagnostic yield from minimal blood samples. The company serves hospitals and public health laboratories, with a mission dedicated to saving lives and improving health outcomes for children by providing advanced testing solutions.
Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured, multiple sclerosis and similar patient populations. By combining novel pharmaceutical agents with drug delivery technology, Dignify Therapeutics will redefine the treatment of these disorders and restore the dignity of voluntary excretory function for these patients.
The company was founded in 2013 and is headquartered in Raleigh, North Carolina.
Panacea Biomatx offers its customers with nutritional supplements that are according to each person’s gender, age, and weight. Customers are able to personalize their mix by choosing a flavor. Panacea Biomatx was founded by Edison Hudson and Staton Noel in January 2013. It is based in Durham, North Carolina.
Jenken Biosciences is a specialty pharmaceutical company focused on developing and commercializing innovative small molecules that act as TLR4 antagonists. Targeting the Toll-Like Receptor 4, which plays a crucial role in mediating inflammatory responses, the company aims to address various conditions linked to chronic inflammation, including chronic liver disease, inflammatory bowel disease, cancer, diabetes, and organ damage in the kidneys and lungs. Jenken's drug development strategy emphasizes reducing time-to-market and minimizing risks and costs by re-profiling already approved drugs. Additionally, the company is advancing a diverse pipeline of novel chemical entities aimed at treating chronic liver disease, inflammatory bowel disease, rheumatoid arthritis, and diabetes, as well as addressing organ damage. By leveraging proprietary technology for cytokine modulation, Jenken seeks to restore kidney function affected by various underlying conditions.